CN113662962A - Hypertonic seawater nasal sprayer - Google Patents
Hypertonic seawater nasal sprayer Download PDFInfo
- Publication number
- CN113662962A CN113662962A CN202110922220.XA CN202110922220A CN113662962A CN 113662962 A CN113662962 A CN 113662962A CN 202110922220 A CN202110922220 A CN 202110922220A CN 113662962 A CN113662962 A CN 113662962A
- Authority
- CN
- China
- Prior art keywords
- stirring
- spray
- seawater
- hypertonic
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Abstract
The invention belongs to the technical field of medical appliances, and particularly relates to a hypertonic seawater nasal cavity sprayer. The invention relates to a hypertonic seawater nasal cavity sprayer which comprises a spraying tank, a nozzle and a nozzle cover, wherein spraying liquid is filled in the spraying tank and comprises the following components in percentage by mass: 0.8-1.6% of sodium bicarbonate, 2-2.5% of sea salt, 0.5-1% of glycerol, 0.5-1.5% of protective agent, 0.3-0.6% of adhesive, 0.003-0.005% of essence and 92.795-95.897% of purified water. The spray liquid in the hypertonic seawater nasal cavity sprayer has no stimulation to nasal mucosa after being sprayed out, has no cilium toxicity, can effectively avoid the damage to the nasal mucosa caused by long-term use, and greatly improves the use safety of the product.
Description
Technical Field
The invention belongs to the technical field of medical appliances, and particularly relates to a hypertonic seawater nasal cavity sprayer.
Background
At present, air pollution is serious, the health of nasal cavities of people is greatly influenced, and people with rhinitis and other problems are increased gradually. Rhinitis, an inflammatory disease of the nasal cavity, is inflammation of the mucous membrane of the nasal cavity caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. The main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of the nasal mucosa. Rhinitis is a common and frequent disease, and clinically shows symptoms of nasal obstruction, rhinorrhea, hyposmia and the like, which brings inconvenience to work and life. The current common treatments for rhinitis are intranasal glucocorticoids, nasal washes, and intranasal decongestants. Among them, nasal cavity cleansing is a relatively simple and effective method. The nasal cavity cleaning is a treatment method which is characterized in that cleaning liquid is conveyed to the nasal cavity by a proper device, and the purposes of cleaning and moistening the nasal cavity, medicament treatment and the like are achieved by the contact of liquid medicine and target tissues of the nasal cavity. At present, the nasal cavity nursing sprayer is an applicable, effective and safe instrument. For rhinitis patients, physiological seawater is used for washing the nasal cavity at regular time, so that discomfort caused by rhinitis can be relieved to a greater extent, and the rhinitis can be cured as soon as possible.
The hypertonic seawater nasal cavity sprayer consists of a spraying tank (filled with spraying liquid), a nozzle and a nozzle cover, wherein the spraying liquid is seawater solution containing 2.3% +/-0.23% (W/W) of chloride (calculated by NaCl). However, the existing hypertonic seawater nasal cavity sprayer has the obvious stimulation effect when the spray liquid is used for washing the nasal cavity, and cannot be frequently used, particularly cannot be continuously used for a long time. Therefore, a hypertonic seawater nasal sprayer which has no stimulation to nasal mucosa and is suitable for long-term use is urgently needed in the market.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a hypertonic seawater nasal cavity sprayer. The spray liquid in the high-permeability seawater nasal cavity sprayer provided by the invention has no stimulation effect on nasal mucosa after being sprayed out, has no cilium toxicity, can effectively avoid damage to the nasal mucosa after long-term use, greatly improves the use safety of products, and solves the technical problems that the spray liquid in the existing high-permeability seawater nasal cavity sprayer has obvious stimulation effect when being used for washing the nasal cavity, cannot be frequently used, particularly cannot be uninterruptedly used for a long time, and is easy to cause mucosa atrophy and the like after being used for a long time.
The technical scheme of the invention is as follows:
a hypertonic seawater nasal cavity sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can and comprises the following components in percentage by mass: 0.8-1.6% of sodium bicarbonate, 2-2.5% of sea salt, 0.5-1% of glycerol, 0.5-1.5% of protective agent, 0.3-0.6% of adhesive, 0.003-0.005% of essence and 92.795-95.897% of purified water.
Further, the hypertonic seawater nasal cavity sprayer comprises a spray tank, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray tank and comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water.
Further, the protective agent is pullulan and trehalose.
Further, the mass ratio of the pullulan to the trehalose is 1 (4-6).
Further, the mass ratio of the pullulan to the trehalose is 1: 5.
Further, the adhesive is carbomer and polyvinyl alcohol.
Further, the mass ratio of the carbomer to the polyvinyl alcohol is (1-3) to (5-8).
Further, the preparation method of the spray liquid comprises the following steps:
s1 adding purified water 7-10 times of sea salt into sea salt, stirring, adding active carbon, and heating to boil to obtain sea water;
s2, firstly, carrying out coarse filtration on the seawater obtained in the step S1 by using a microfiltration membrane with the pore diameter of 0.45 mu m, then, carrying out secondary filtration by using a microfiltration membrane with the pore diameter of 0.22 mu m, and cooling to room temperature to obtain filtered seawater;
s3 adding protective agent under stirring at the speed of 250-400r/min, adding adhesive after stirring for 10-20min, adding glycerol and essence after stirring for 30-50min, adding sodium bicarbonate after stirring for 20-30min, adding the rest purified water after stirring for 15-25min, stirring for 40-60min, and filtering to obtain the product.
The protective agent consisting of pullulan polysaccharide and trehalose according to a specific mass ratio added in the invention can effectively protect nasal mucosa, so that the product does not generate irritation to the nasal cavity, the damage to the nasal mucosa caused by long-term use is effectively avoided, the use safety of the product is greatly improved, the action time of active ingredients can be prolonged, and the use effect of the product is improved. The adhesive which is added in the invention and consists of carbomer and polyvinyl alcohol in a specific mass ratio can further prolong the action time of the active ingredients and improve the durability of the using effect of the product.
After the spray liquid in the high-permeability seawater nasal cavity sprayer is sprayed out, the spray liquid can directly reach focuses through high-permeability seawater, nasal cavity edema can be quickly relieved, secretion generated by nasal mucosa edema is eliminated, pathogenic bacteria, dust mites and allergen in the nasal cavity can be thoroughly washed, the nasal cavity is clean and moist, physiological functions of the nasal cavity are improved, the nasal cavity is effectively cleaned on the premise of safety and comfort, the high-permeability seawater nasal cavity sprayer has a good effect on allergic rhinitis symptoms such as sneeze, watery nasal discharge, nasal obstruction, rhinocnesmus and the like, and discomfort caused by allergic rhinitis can be relieved to a great extent.
The invention relates to a using method of a hypertonic seawater nasal cavity sprayer, which comprises the following steps: usually, it is used 3-4 times per day. More frequent use is also possible if desired.
Compared with the prior art, the invention has the following advantages:
(1) the spray liquid in the hypertonic seawater nasal cavity sprayer provided by the invention has the functions of remarkably eliminating nasal mucosa edema and promoting nasal cilia to swing, can be sprayed out by a spray system, can effectively carry out deep cleaning and cleaning on the nasal cavity, is used for washing the nasal cavity, can remove secretion generated by the nasal mucosa edema, and can clean and moisten the nasal cavity.
(2) The spray liquid in the hypertonic seawater nasal cavity sprayer provided by the invention has no stimulation effect on nasal mucosa after being sprayed out, has no cilium toxicity, can not cause atrophy of the nasal mucosa after being used for a long time, has excellent safety, and solves the technical problems that the spray liquid in the existing hypertonic seawater nasal cavity sprayer has obvious stimulation effect when being used for washing the nasal cavity, can not be frequently used, particularly can not be uninterruptedly used for a long time, can easily cause atrophy of the nasal mucosa after being used for a long time and the like.
Detailed Description
The present invention is further described in the following description of the specific embodiments, which is not intended to limit the invention, but various modifications and improvements can be made by those skilled in the art according to the basic idea of the invention, within the scope of the invention, as long as they do not depart from the basic idea of the invention.
Example 1A nasal nebulizer with hypertonic seawater
The high-permeability seawater nasal sprayer comprises a spraying tank, a nozzle and a nozzle cover, wherein spraying liquid is filled in the spraying tank and comprises the following components in percentage by mass: 0.8% of sodium bicarbonate, 2% of sea salt, 0.5% of glycerol, 0.5% of protective agent, 0.3% of adhesive, 0.003% of essence and 95.897% of purified water; the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 4; the adhesive is composed of carbomer 941 and polyvinyl alcohol 1788 in a mass ratio of 1: 8.
The preparation method of the spray liquid comprises the following steps:
s1 adding purified water 7 times of sea salt into sea salt, stirring, adding active carbon, and heating to boil to obtain sea water;
s2, firstly, carrying out coarse filtration on the seawater obtained in the step S1 by using a microfiltration membrane with the pore diameter of 0.45 mu m, then, carrying out secondary filtration by using a microfiltration membrane with the pore diameter of 0.22 mu m, and cooling to room temperature to obtain filtered seawater;
s3 adding protective agent under stirring at 250r/min, adding adhesive after stirring for 10min, adding glycerol and essence after stirring for 30min, adding sodium bicarbonate after stirring for 20min, adding the rest purified water after stirring for 15min, stirring for 40min, and filtering to obtain the final product.
Example 2A nasal nebulizer with hypertonic seawater
The high-permeability seawater nasal sprayer comprises a spraying tank, a nozzle and a nozzle cover, wherein spraying liquid is filled in the spraying tank and comprises the following components in percentage by mass: 1.6% of sodium bicarbonate, 2.5% of sea salt, 1% of glycerol, 1.5% of protective agent, 0.6% of adhesive, 0.005% of essence and 92.795% of purified water; the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 6; the adhesive is composed of carbomer 941 and polyvinyl alcohol 1788 in a mass ratio of 3: 5.
The preparation method of the spray liquid comprises the following steps:
s1 adding purified water 10 times of sea salt into sea salt, stirring, adding active carbon, and heating to boil to obtain sea water;
s2, firstly, carrying out coarse filtration on the seawater obtained in the step S1 by using a microfiltration membrane with the pore diameter of 0.45 mu m, then, carrying out secondary filtration by using a microfiltration membrane with the pore diameter of 0.22 mu m, and cooling to room temperature to obtain filtered seawater;
s3 adding protective agent under stirring at 400r/min, adding adhesive after stirring for 20min, adding glycerol and essence after stirring for 50min, adding sodium bicarbonate after stirring for 30min, adding the rest purified water after stirring for 25min, stirring for 60min, and filtering.
Example 3A nasal nebulizer with hypertonic seawater
The hypertonic seawater nasal cavity sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can and comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water; the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 5; the adhesive is composed of carbomer 941 and polyvinyl alcohol 1788 in a mass ratio of 2: 7.
The preparation method of the spray liquid comprises the following steps:
s1 adding purified water 8 times of sea salt into sea salt, stirring, adding active carbon, and heating to boil to obtain sea water;
s2, firstly, carrying out coarse filtration on the seawater obtained in the step S1 by using a microfiltration membrane with the pore diameter of 0.45 mu m, then, carrying out secondary filtration by using a microfiltration membrane with the pore diameter of 0.22 mu m, and cooling to room temperature to obtain filtered seawater;
s3 adding protective agent under stirring at 350r/min, adding adhesive after stirring for 15min, adding glycerol and essence after stirring for 45min, adding sodium bicarbonate after stirring for 25min, adding the rest purified water after stirring for 20min, stirring for 50min, and filtering.
Comparative example 1, a hypertonic seawater nasal sprayer
The hypertonic seawater nasal cavity sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can and comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water; the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 1; the adhesive is composed of carbomer 941 and polyvinyl alcohol 1788 in a mass ratio of 2: 7.
The spray solution was prepared analogously to example 3.
The difference from the example 3 is that the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 1.
Comparative example 2, a hypertonic seawater nasal sprayer
The hypertonic seawater nasal cavity sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can and comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water; the protective agent is trehalose; the adhesive is composed of carbomer 941 and polyvinyl alcohol 1788 in a mass ratio of 2: 7.
The spray solution was prepared analogously to example 3.
The difference from example 3 is that the protective agent is trehalose.
Comparative example 3, a hypertonic seawater nasal sprayer
The hypertonic seawater nasal cavity sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can and comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water; the protective agent consists of pullulan and trehalose according to the mass ratio of 1: 5; the adhesive is polyvinyl alcohol 1788.
The spray solution was prepared analogously to example 3.
The difference from example 3 is that the adhesive is polyvinyl alcohol 1788.
Test example I, local mucosal irritation test
30 rabbits with 2kg weight and half female and half male were selected. 30 rabbits were divided into 3 groups on average, i.e., example 1 group, example 2 group, and example 3 group, 10 rabbits each, and male and female halves. Each rabbit was sprayed 5 times daily with the corresponding hypertonic seawater nasal spray for 7 consecutive days. No irritation was observed within 30min after daily administration. Rabbits were dissected 24h after the last dose (i.e., day 8), and the nasal cavity of the rabbits was removed for observation. And observing whether the nasal mucosa surface of each group of rabbits has bleeding spots, congestion, red swelling and the like.
No sneezing, nasal obstruction, congestion, edema, secretion and other phenomena appeared in all the rabbits within 30min after the administration every day. The rabbits were dissected 24 hours after the last administration, and the nasal cavities of the rabbits were taken out for observation, and it was found that the nasal mucosa surfaces of the rabbits in each group did not show bleeding spots, congestion, red swelling, etc. The result of the local mucosa irritation test shows that the hypertonic seawater nasal cavity sprayer does not cause irritation to the nasal cavity when used for washing the nasal cavity, and has good safety.
Test example two evaluation of cilia toxicity
40 Chinese toads with weight of 50g and half of male and female are selected. The bufonid chinensis was divided into 4 groups, namely, normal saline group, example 1 group, example 2 group and example 3 group, 10 bufonid per group, each half of male and female. The bufo gargarizans is fixed on a frog board in a supine way, the oral cavity is opened by hemostatic forceps, and 0.2mL of corresponding solution is respectively dripped on the mucous membrane. Physiological saline was added dropwise to the physiological saline group, and the spray solutions prepared in examples 1, 2, and 3 were added dropwise to the physiological saline group, respectively. After the device is placed for 0.5h, the palatal mucosa is separated by an operating scissors, the mucosa with the thickness of about 3mm multiplied by 3mm is taken, the blood clot and impurities are cleaned by normal saline, the mucous membrane is laid on a glass slide, a cover glass is covered, the swinging condition of mucociliary and the morphological change of the mucosa are observed under a microscope until the ciliary stops moving, the continuous moving time of the ciliary is recorded, and the continuous moving percentage of the ciliary is calculated. The cilia duration of movement is the time from administration to cessation of movement of the cilia. The percentage of ciliary continuous movement was the ciliary continuous movement time of each example group divided by the ciliary continuous movement time of the saline group, and the data of the test are shown in Table 1.
Table 1: influence of spray liquid on ciliary continuous movement
| Group of | Cilium duration of movement (min) | Percentage of cilia sustained movement (%) |
| Physiological saline group | 574.8 | 100 |
| EXAMPLE 1 group | 532.3 | 92.6 |
| EXAMPLE 2 group | 542.6 | 94.4 |
| EXAMPLE 3 group | 554.7 | 96.5 |
As can be seen from table 1, the cilia continuous movement time of the spray liquid prepared in examples 1 to 3 of the present invention was not significantly different from that of the normal saline solution group, and it was found by observation that the cilia were clear and complete, arranged neatly, moved actively, and did not drop off after the spray liquid prepared in examples 1 to 3 of the present invention was administered. This indicates that the spray solutions prepared in examples 1-3 of the present invention had substantially no effect on ciliary movement and were not considered toxic to cilia.
Test example three, evaluation of Using Effect
72 allergic rhinitis patients meeting the allergic rhinitis diagnosis standard are screened and randomly divided into an example 3 group, a comparative example 1 group, a comparative example 2 group and a comparative example 3 group, wherein each group comprises 18 patients, and the application method comprises the following steps: the nasal spray is applied to nasal cavity in the morning and evening, and the application time is 7 days. The physical sign scoring and symptom scoring are respectively carried out on the subjects before and after use according to the national allergic rhinitis scoring standard. The sign scoring criteria are shown in table 2, and the symptom scoring criteria are shown in table 3. The percentage of improvement in the symptom complex is (total before use-total after use)/total before use × 100%. The improvement percentage of the comprehensive symptoms is more than or equal to 66 percent, and the effect is obvious; the improvement percentage of the comprehensive symptoms is 26 to 65 percent, which is effective; failure to meet the above criteria is ineffective. The total effective is significant effect plus effective. Meanwhile, after the use is stopped for 1 month, the existence of adverse reactions such as nasal cavity capillary atrophy and the like of the testee is observed. The test data are shown in Table 4.
Table 2: sign scoring standard
Table 3: symptom scoring criteria
| Grading scoring | Sneezing* | Running nose△ | Nasal obstruction | Itching of nose |
| 1 minute (1) | 3-5 | ≤4 | Conscious feeling during inspiration | Is interrupted by |
| 2 is divided into | 6-10 | 5-9 | Intermittent or interactive | The sense of ant but can be tolerated |
| 3 points of | ≥11 | ≥10 | Oral respiration almost all day | An undigested and impatient feeling of the ants |
Note:*number of 1 continuous sneeze;△blowing nose every day.
Table 4: evaluation of Using Effect
| Group of | Effective rate (%) | The number of people with atrophy of nasal capillaries |
| EXAMPLE 3 group | 100 | 0 |
| Comparative example 1 group | 88.9 | 3 |
| Comparative example 2 group | 83.3 | 8 |
| Comparative example 3 group | 83.3 | 5 |
As can be seen from Table 4, compared with the groups of comparative examples 1 to 3, the hypertonic seawater nasal nebulizer provided by the invention can significantly improve the symptoms of nasal obstruction, sneezing, rhinocnesmus and the like of allergic rhinitis, and has good effect on allergic rhinitis. In addition, after 1 month of discontinuation of use, the group of example 3 had no atrophy of nasal capillaries, while the group of comparative example 1 had 3 subjects with atrophy of nasal capillaries, the group of comparative example 2 had 8 subjects with atrophy of nasal capillaries, and the group of comparative example 3 had 5 subjects with atrophy of nasal capillaries. Therefore, the hypertonic seawater nasal cavity sprayer is not easy to cause the phenomenon of nasal mucosa atrophy.
Claims (8)
1. The high-permeability seawater nasal sprayer comprises a spray can, a nozzle and a nozzle cover, wherein spray liquid is filled in the spray can, and the high-permeability seawater nasal sprayer is characterized by comprising the following components in percentage by mass: 0.8-1.6% of sodium bicarbonate, 2-2.5% of sea salt, 0.5-1% of glycerol, 0.5-1.5% of protective agent, 0.3-0.6% of adhesive, 0.003-0.005% of essence and 92.795-95.897% of purified water.
2. The hypertonic seawater nasal cavity sprayer of claim 1, which consists of a spray can, a nozzle and a nozzle cover, wherein the spray can contains spray liquid, and the spray liquid comprises the following components in percentage by mass: 1.2% of sodium bicarbonate, 2.3% of sea salt, 0.8% of glycerol, 1% of protective agent, 0.5% of adhesive, 0.004% of essence and 94.196% of purified water.
3. The hypertonic seawater nasal nebulizer of claim 1 or 2 wherein the protectant agent is pullulan and trehalose.
4. The hypertonic seawater nasal nebulizer of claim 3 wherein the mass ratio of pullulan to trehalose is 1 (4-6).
5. The hypertonic seawater nasal nebulizer of claim 4 wherein the mass ratio of pullulan to trehalose is 1: 5.
6. The hypertonic seawater nasal nebulizer of claim 1 or 2 wherein the adhesive is carbomer and polyvinyl alcohol.
7. The hypertonic seawater nasal nebulizer of claim 6 wherein the mass ratio of carbomer to polyvinyl alcohol is (1-3) to (5-8).
8. The hypertonic seawater nasal nebulizer of any one of claims 1-7 wherein the spray is prepared by:
s1 adding purified water 7-10 times of sea salt into sea salt, stirring, adding active carbon, and heating to boil to obtain sea water;
s2, firstly, carrying out coarse filtration on the seawater obtained in the step S1 by using a microfiltration membrane with the pore diameter of 0.45 mu m, then, carrying out secondary filtration by using a microfiltration membrane with the pore diameter of 0.22 mu m, and cooling to room temperature to obtain filtered seawater;
s3 adding protective agent under stirring at the speed of 250-400r/min, adding adhesive after stirring for 10-20min, adding glycerol and essence after stirring for 30-50min, adding sodium bicarbonate after stirring for 20-30min, adding the rest purified water after stirring for 15-25min, stirring for 40-60min, and filtering to obtain the product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110922220.XA CN113662962B (en) | 2021-08-12 | 2021-08-12 | Hypertonic seawater nasal sprayer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110922220.XA CN113662962B (en) | 2021-08-12 | 2021-08-12 | Hypertonic seawater nasal sprayer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662962A true CN113662962A (en) | 2021-11-19 |
| CN113662962B CN113662962B (en) | 2022-04-22 |
Family
ID=78542452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110922220.XA Active CN113662962B (en) | 2021-08-12 | 2021-08-12 | Hypertonic seawater nasal sprayer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662962B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115590899A (en) * | 2022-09-19 | 2023-01-13 | 自然资源部天津海水淡化与综合利用研究所（Cn） | Preparation method of compound deep-sea nasal wash salt |
| CN115590878A (en) * | 2022-10-14 | 2023-01-13 | 云飞生物药业（吉林）有限公司（Cn） | Hypertonic seawater nasal spray |
| CN116211884A (en) * | 2023-02-16 | 2023-06-06 | 海孵(海南自贸区)医疗科技有限责任公司 | Nasal cavity spray and preparation method thereof |
| CN116211884B (en) * | 2023-02-16 | 2024-05-17 | 海孵(海南自贸区)医疗科技有限责任公司 | Nasal cavity spray and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN206934319U (en) * | 2016-12-02 | 2018-01-30 | 广州零界医药有限公司 | A kind of adjustable nasal cavity flusher |
| CN109394837A (en) * | 2018-10-22 | 2019-03-01 | 吉林省七维生物科技有限公司 | A kind of nasal mist and preparation method thereof |
| CN213374687U (en) * | 2020-09-14 | 2021-06-08 | 广州零界医药有限公司 | Nasal sprayer |
-
2021
- 2021-08-12 CN CN202110922220.XA patent/CN113662962B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN206934319U (en) * | 2016-12-02 | 2018-01-30 | 广州零界医药有限公司 | A kind of adjustable nasal cavity flusher |
| CN109394837A (en) * | 2018-10-22 | 2019-03-01 | 吉林省七维生物科技有限公司 | A kind of nasal mist and preparation method thereof |
| CN213374687U (en) * | 2020-09-14 | 2021-06-08 | 广州零界医药有限公司 | Nasal sprayer |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115590899A (en) * | 2022-09-19 | 2023-01-13 | 自然资源部天津海水淡化与综合利用研究所（Cn） | Preparation method of compound deep-sea nasal wash salt |
| CN115590878A (en) * | 2022-10-14 | 2023-01-13 | 云飞生物药业（吉林）有限公司（Cn） | Hypertonic seawater nasal spray |
| CN116211884A (en) * | 2023-02-16 | 2023-06-06 | 海孵(海南自贸区)医疗科技有限责任公司 | Nasal cavity spray and preparation method thereof |
| CN116211884B (en) * | 2023-02-16 | 2024-05-17 | 海孵(海南自贸区)医疗科技有限责任公司 | Nasal cavity spray and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113662962B (en) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113662962B (en) | Hypertonic seawater nasal sprayer | |
| Pavilack et al. | Thorough curettage in the treatment of chronic canaliculitis | |
| CN103182070B (en) | External composition, and preparation and application thereof | |
| CN109394837A (en) | A kind of nasal mist and preparation method thereof | |
| CN113694024B (en) | Physiological seawater nasal cavity sprayer | |
| CN107899006A (en) | Pharmaceutical composition of nasal irrigation and preparation method thereof | |
| Cannon | The problem of lipid pneumonia: a brief review | |
| US20220193174A1 (en) | Nasal spray for preventing influenza based on red pepper extract and heparin and preparation method thereof | |
| Melland | THE TREATMENT OF SPASMODIC ASTHMA BY THE HYPODERMIC INJECTION OF ADRENALIN. | |
| CN103877288A (en) | Biomedical film made of chitosan for nasopharyngitis and preparation method thereof | |
| CA2852591C (en) | Vitamin d3 compositions and uses thereof for the treatment of nasal passages | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN110876715A (en) | Nasal cavity flushing fluid | |
| Keen | Medical and surgical complications of tonsillectomy in childhood | |
| CN110917138B (en) | Two-cavity nasal spray containing oxymetazoline hydrochloride for treating rhinitis | |
| JP6232631B2 (en) | Biofilm agent | |
| CN116585404B (en) | External traditional Chinese medicine composition for treating adult simple skin pruritus and preparation method thereof | |
| KR100785441B1 (en) | Physiological saline solution with antibacterial activity comprising minerals of deep sea water | |
| CN113413444A (en) | Nasal cavity flushing fluid and preparation method thereof | |
| CN117695223A (en) | Oligosaccharide atomizing agent based on guluronic acid oligosaccharide and preparation method thereof | |
| Walters et al. | Corneal problems in burned patients | |
| Brown | LV Intrasinal Application of Sulfonamide Powder | |
| CN117180204A (en) | Nasal cavity dry powder gel and preparation method thereof | |
| SU577031A1 (en) | 'benzodiocaine'anesthetic for ophtalmology and otolaryngology | |
| CN114081929A (en) | A Chinese medicinal composition for treating rhinitis, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |